Clinical Study

A Randomized, Phase II Trial Of Intermittent Versus Continuous Dosing Of Dabrafenib (Nsc-763760) And Trametinib (Nsc-763093) In Brafv600e/K Mutant Mel

Posted Date: May 15, 2019

  • Investigator: John Morris
  • Type of Study: Drug

The purpose of this study is to compare good and bad effects of receiving the drugs dabrafenib and trametinib continuously to receiving dabrafenib and trametinib with a break in treatment. The combination has been approved by the FDA for the treatment of advanced melanoma. This study will allow rese


To Be Eligible For This Study, Patients Must Have Melanoma With The Braf Mutation.


Melanoma, Mutant , Cancer, Skin Cancer, S1320

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.